A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Active, not recruiting · Phase 2 · NCT06413706
Conditions: Glioma
At a glance
- Research payments reported, 2025
- $549,371
- U.S. investigators named
- 14
- Sites paid
- 14
- Planned or actual enrollment
- 45
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Abemaciclib (drug), Temozolomide (drug)
- Dates
- Started 2024-10-25; completion 2028-02
- Results posted
- Not yet
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
From ClinicalTrials.gov, last updated 2026-07-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $549,371 in research payments for this study in 2025 (21 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael R. Mangum Pediatric Hematology & Oncology · Phoenix, AZ
- Sonia Partap, MD Child Neurology · Palo Alto, CA
- Mariko Sato, M.D., PH.D. Pediatric Hematology & Oncology · Orange, CA
- Jessica Schulte, M.D., PH.D. Neurology · San Diego, CA
- Ziad Khatib, MD Pediatric Hematology & Oncology · Miami, FL
- Scott Coven, D.O. Pediatric Hematology & Oncology · Indianapolis, IN
- Kenneth Cohen, M.D. Pediatric Hematology & Oncology · Baltimore, MD
- Andrea T. Franson, MD Pediatric Hematology & Oncology · Ann Arbor, MI
- David J. Hoogstra, MD Pediatric Hematology & Oncology · Grand Rapids, MI
- Bradley D. Denardo, MD Pediatric Hematology & Oncology · Providence, RI
- Lindsay B. Kilburn, MD Pediatric Hematology & Oncology · Houston, TX
- Diana S. Osorio, M.D. Pediatric Hematology & Oncology · Houston, TX
- Jonathan D. Schwartz, D.O. Pediatric Hematology & Oncology · Fort Worth, TX
- Avanthi T. Shah, MD Pediatric Hematology & Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Michigan Health System, MI $92,454
- Regents of the University of California $73,735
- Ut MD Anderson Cancer Center $53,203
- Indiana University $53,001
- The University of Texas $38,003
- Children's Hospital of Orange County, CA $35,344
- Mayo Clinic $32,360
- $29,291
- Board of Trustees of the Leland Stanford Jr Univ $28,811
- Phoenix Children's Hospital, AZ $26,000
- Nicklaus Children's Hospital, FL $24,925
- Corewell Health $22,195
- Childrens Research Institute $18,178
- Johns Hopkins University $17,567
- Rhode Island Hospital, RI $4,304
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.